

# Annalisa Chiarenza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6587191/publications.pdf>

Version: 2024-02-01

109  
papers

3,682  
citations

279487

23  
h-index

133063

59  
g-index

109  
all docs

109  
docs citations

109  
times ranked

6590  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the coding genome of diffuse large B-cell lymphoma. <i>Nature Genetics</i> , 2011, 43, 830-837.	9.4	871
2	Inactivating mutations of acetyltransferase genes in B-cell lymphoma. <i>Nature</i> , 2011, 471, 189-195.	13.7	822
3	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
4	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
5	CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 1212-1216.	0.4	124
6	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
7	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). <i>Oncotarget</i> , 2016, 7, 85764-85775.	0.8	80
8	Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated upfront with a risk-adapted strategy. <i>British Journal of Haematology</i> , 2015, 168, 689-700.	1.2	76
9	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients. <i>PLoS ONE</i> , 2014, 9, e101848.	1.1	71
10	Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. <i>International Journal of Cancer</i> , 2012, 131, 2197-2203.	2.3	70
11	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	4.2	65
12	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
13	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	0.8	54
14	Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up. <i>World Journal of Gastroenterology</i> , 2014, 20, 12993.	1.4	49
15	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. <i>Annals of Hematology</i> , 2018, 97, 1009-1018.	0.8	44
16	Effects of imatinib mesylate in osteoblastogenesis. <i>Experimental Hematology</i> , 2009, 37, 461-468.	0.2	41
17	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
18	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. <i>Cancer</i> , 2006, 106, 1188-1196.	2.0	33

#	ARTICLE	IF	CITATIONS
19	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	0.6	33
20	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. <i>PLoS ONE</i> , 2016, 11, e0158392.	1.1	30
21	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
22	The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. <i>Oncotarget</i> , 2016, 7, 67333-67346.	0.8	27
23	Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. <i>Hematological Oncology</i> , 2012, 30, 27-33.	0.8	26
24	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	3.2	23
25	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	1.3	22
26	<i>NOTCH1</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	1.2	22
27	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115.	3.3	21
28	Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi ( <i>FIL</i> ). <i>British Journal of Haematology</i> , 2019, 185, 713-717.	1.2	21
29	Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the <i>FOLL05</i> trial of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2015, 169, 544-551.	1.2	20
30	Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive. <i>Blood</i> , 2013, 122, 3138-3138.	0.6	20
31	Salvage Therapy of Multiple Myeloma: The New Generation Drugs. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	18
32	Mutations in the 5' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	1.7	18
33	CD200 expression in patients with Multiple Myeloma: Another piece of the puzzle. <i>Leukemia Research</i> , 2013, 37, 1616-1621.	0.4	17
34	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 841-847.	0.6	17
35	Prognostic Assessment and Treatment of Primary Gastric Lymphomas: How Endoscopic Ultrasonography Can Help in Tailoring Patient Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 179-185.	0.2	17
36	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5459.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 468-479.	1.2	17
38	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
39	Rare gastrointestinal lymphomas: The endoscopic investigation. <i>World Journal of Gastrointestinal Endoscopy</i> , 2015, 7, 928.	0.4	16
40	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. <i>BMC Cancer</i> , 2013, 13, 60.	1.1	15
41	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	2.0	15
42	A laboratory-based scoring system predicts early treatment in Rai O chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
43	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	6.9	14
44	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, . .	2.5	14
45	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. <i>European Journal of Haematology</i> , 2014, 93, 207-213.	1.1	12
46	&lt;i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	1.7	12
47	Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up. <i>Hematological Oncology</i> , 2012, 30, 180-185.	0.8	11
48	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	1.7	11
49	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. <i>European Journal of Haematology</i> , 2020, 104, 581-587.	1.1	10
50	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
51	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	3.3	8
52	Predictive value of the <sc>CLL</sc>â€<sc>IPI</sc> in <sc>CLL</sc> patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	1.1	8
53	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353.	1.7	8
54	<sc>i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. Blood Cancer Journal, 2020, 10, 92.	2.8	7
56	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European Journal of Haematology, 2011, 86, 216-225.	1.1	6
57	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	1.1	5
58	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 2014, 38, 198-203.	0.4	4
59	A brief rituximab, bendamustine, mitoxantrone (R+BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). British Journal of Haematology, 2021, 193, 280-289.	1.2	4
60	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). Blood, 2011, 118, 777-777.	0.6	4
61	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. Cancers, 2022, 14, 1173.	1.7	4
62	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	2.0	3
63	Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib. Blood, 2015, 126, 2767-2767.	0.6	3
64	Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma.. Blood, 2009, 114, 3662-3662.	0.6	3
65	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. Blood, 2020, 136, 25-26.	0.6	3
66	Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 554-557.	0.6	2
67	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4396-4396.	0.6	2
68	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. Blood, 2020, 136, 54-55.	0.6	2
69	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. Blood Advances, 2022, 6, 3875-3878.	2.5	2
70	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2007, 110, 4672-4672.	0.6	1
71	Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).. Blood, 2012, 120, 2720-2720.	0.6	1
72	Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma. Blood, 2016, 128, 1770-1770.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Role of Imatinib Mesylate in Osteoblastogenesis.. Blood, 2007, 110, 1928-1928.	0.6	1
74	Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma. Blood, 2013, 122, 4238-4238.	0.6	1
75	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. Blood, 2016, 128, 4358-4358.	0.6	1
76	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). Blood, 2021, 138, 3746-3746.	0.6	1
77	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. † Training/Validation Study. Blood, 2020, 136, 31-32.	0.6	1
78	Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S11-S12.	0.2	0
79	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. Blood, 2006, 108, 4981-4981.	0.6	0
80	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. Blood, 2006, 108, 4387-4387.	0.6	0
81	Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamethasone in Previously Treated Myeloma Patients.. Blood, 2007, 110, 2728-2728.	0.6	0
82	Role of New Tyrosine Kinase Inhibitors in Osteoblastogenesis. Blood, 2008, 112, 4751-4751.	0.6	0
83	Variation of T-Reg and CD 200+ T- Lymphocytes After in Vitro Treatment with Active Drugs against CLL.. Blood, 2009, 114, 1239-1239.	0.6	0
84	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. Blood, 2009, 114, 1220-1220.	0.6	0
85	Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma. Blood, 2010, 116, 3882-3882.	0.6	0
86	Genome-Wide Analysis Reveals Frequent Inactivating Mutations of Acetyltransferase Genes In B-Cell Lymphoma. Blood, 2010, 116, 474-474.	0.6	0
87	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. Blood, 2013, 122, 2711-2711.	0.6	0
88	Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. Journal of Clinical Oncology, 2014, 32, 8530-8530.	0.8	0
89	Up-Regulation of Prok-2 in Granulocytes Is Present BOTH in MGUS and MM. Blood, 2014, 124, 5694-5694.	0.6	0
90	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Arginase-1 Is Increased in Hodgkin Lymphoma, Associated to Poor Outcome and Positively Correlated to Semiquantitative PET Parameters. <i>Blood</i> , 2014, 124, 4401-4401.	0.6	0
92	Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication. <i>Blood</i> , 2015, 126, 1708-1708.	0.6	0
93	Management of Grade 3B Follicular Lymphoma (FL) Outside Clinical Trials: A Multicentric Retrospective Analysis on Behalf of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 2716-2716.	0.6	0
94	Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 3933-3933.	0.6	0
95	Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients. <i>Blood</i> , 2015, 126, 4018-4018.	0.6	0
96	The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1720-1720.	0.6	0
97	LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 3985-3985.	0.6	0
98	The Combined Evaluation of Neutrophil, T-Lymphocyte and Monocyte Counts Provides New Prognostic Information in CLL Patients. <i>Blood</i> , 2016, 128, 5565-5565.	0.6	0
99	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.	0.6	0
100	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354.	0.6	0
101	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195.	0.6	0
102	The VLA-4 Integrin Is Constitutively Activated in a Subset of CD49d-Expressing CLL: A Relationship with the Autonomous BCR-Mediated Signaling?. <i>Blood</i> , 2018, 132, 5531-5531.	0.6	0
103	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. <i>Blood</i> , 2018, 132, 944-944.	0.6	0
104	SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. <i>Blood</i> , 2018, 132, 1838-1838.	0.6	0
105	Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 945-945.	0.6	0
106	KRAS, NRAS and BRAF Mutations Are Highly Enriched in TR112 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. <i>Blood</i> , 2018, 132, 3113-3113.	0.6	0
107	A Laboratory Based Scoring System Predicts Early Treatment in Rai O/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399.	0.6	0
108	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study. <i>Blood</i> , 2020, 136, 48-50.	0.6	0